Literature DB >> 18388043

The roles of oxidized low-density lipoprotein and interleukin-6 levels in acute atherothrombotic and lacunar ischemic stroke.

Baburhan Guldiken1, Sibel Guldiken, Burhan Turgut, Nilda Turgut, Muzaffer Demir, Yahya Celik, Ender Arikan, Armagan Tugrul.   

Abstract

The role of circulating, oxidized low-density lipoprotein and interleukin-6 levels in acute ischemic stroke considering the primary-vessel disease was investigated. The study consisted of 28 patients with acute ischemic stroke and 23 control subjects. Patients were subdivided into large-vessel (n = 12) and small-vessel (n =16) disease stroke groups according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria. The means of oxidized low-density lipoprotein and interleukin-6 levels of patients with acute ischemic stroke were higher than controls (P < .01, P < .05). Mean oxidized low-density lipoprotein level was higher in the large-vessel disease group than in the small-vessel disease group (P < .01). The mean of inteleukin-6 levels was higher in the small-vessel disease group (P < .01). The results of the present study showed that oxidative stress promotes large-vessel disease rather than small-vessel disease stroke, and inflammation may play important an role in the development of small-vessel disease stroke.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18388043     DOI: 10.1177/0003319707304134

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  9 in total

Review 1.  Epigenetics and social context: implications for disparity in cardiovascular disease.

Authors:  Karen L Saban; Herbert L Mathews; Holli A DeVon; Linda W Janusek
Journal:  Aging Dis       Date:  2014-10-01       Impact factor: 6.745

Review 2.  Oxidative risk for atherothrombotic cardiovascular disease.

Authors:  Jane A Leopold; Joseph Loscalzo
Journal:  Free Radic Biol Med       Date:  2009-09-12       Impact factor: 7.376

3.  Association of clinical and aetiologic subtype of acute ischaemic stroke with inflammation, oxidative stress and vascular function: a cross-sectional observational study.

Authors:  Christopher Beer; David Blacker; Graeme J Hankey; Ian B Puddey
Journal:  Med Sci Monit       Date:  2011-09

Review 4.  The Potential Impact of Neuroimaging and Translational Research on the Clinical Management of Lacunar Stroke.

Authors:  Salvatore Rudilosso; Alejandro Rodríguez-Vázquez; Xabier Urra; Adrià Arboix
Journal:  Int J Mol Sci       Date:  2022-01-28       Impact factor: 5.923

5.  Flaxseed lignan complex administration in older human type 2 diabetics manages central obesity and prothrombosis-an invitation to further investigation into polypharmacy reduction.

Authors:  D E Barre; K A Mizier-Barre; E Stelmach; J Hobson; O Griscti; A Rudiuk; D Muthuthevar
Journal:  J Nutr Metab       Date:  2012-10-04

6.  Statin therapy reduces oxidized low density lipoprotein level, a risk factor for stroke outcome.

Authors:  Nai-Wen Tsai; Lian-Hui Lee; Chi-Ren Huang; Wen-Neng Chang; Ya-Ting Chang; Yu-Jih Su; Yi-Fang Chiang; Hung-Chen Wang; Ben-Chung Cheng; Wei-Che Lin; Chia-Te Kung; Chih-Min Su; Yu-Jun Lin; Cheng-Hsien Lu
Journal:  Crit Care       Date:  2014-01-14       Impact factor: 9.097

7.  Interleukin-6 Levels in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.

Authors:  Zheng Peng; Yifan Sun; Xiaolan Lv; Hongyu Zhang; Chunming Liu; Shengming Dai
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

8.  The relationship between oxidized low-density lipoprotein and related ratio and acute cerebral infarction.

Authors:  Zhen Yan; Baosheng Fu; Dan He; Yudi Zhang; Juanjuan Liu; Xiangjian Zhang
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.889

9.  Prestroke statins use reduces oxidized low density lipoprotein levels and improves clinical outcomes in patients with atrial fibrillation related acute ischemic stroke.

Authors:  Lanying He; Ronghua Xu; Jian Wang; Lili Zhang; Lijuan Zhang; Wang Zhao; Weiwei Dong
Journal:  BMC Neurol       Date:  2019-10-18       Impact factor: 2.474

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.